Summit Therapeutics (NASDAQ:SMMT) was given a new $40.00 price target on by analysts at Piper Sandler.
Summit Therapeutics (NASDAQ:SMMT) had its "buy" rating reaffirmed by analysts at HC Wainwright.
Is Summit Therapeutics (SMMT) Still Attractive After Recent Pullback And Multi Year Surge [Yahoo! Finance]
Summit Therapeutics (SMMT) Is Down 8.7% After Ivonescimab BLA Filing And Oncology Expansion Update – Has The Bull Case Changed? [Yahoo! Finance]
2 Biotech Stocks That Could Soar This Year [Yahoo! Finance]